Dongge Yang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of immunology, particularly in the development of innovative antibody constructs. With a total of 2 patents, his work focuses on enhancing the efficacy of therapeutic antibodies.

Latest Patents

Dongge Yang's latest patents include groundbreaking inventions such as "Heterodimeric immunoglobulin constructs and preparation methods thereof." This invention provides a method for producing stable and highly specific heterodimeric immunoglobulin constructs, such as bispecific antibodies. These constructs retain the desirable properties of native IgG while eliminating undesirable heavy chain-light chain mispairing. They can simultaneously bind to two target molecules, making them more potent in treating complex diseases. Another notable patent is "Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody." This patent describes an antibody that specifically binds to IL-17A or its functional fragments, including chimeric and humanized antibodies.

Career Highlights

Throughout his career, Dongge Yang has worked with notable companies, including Beijing Hanmi Pharmaceutical Co., Ltd. and Beijing Hanmi Pharm. Co., Ltd. His expertise in immunology and antibody development has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Dongge Yang has collaborated with esteemed colleagues such as Jiawang Liu and Nanmeng Song. These partnerships have furthered his research and contributed to the advancement of immunological therapies.

Conclusion

Dongge Yang's innovative work in the field of immunoglobulin constructs has the potential to revolutionize treatments for complex diseases. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.